From: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
Risk Factor
HR
95% CI
P value
Assigned score
Absence of AEa in first 4 weeks
1.60
(1.22, 2.11)
0.001
2
> 2 metastasis sites
1.62
(1.21, 2.17)
ECOG PS > 0
2.48
(1.70, 3.61)
< 0.001
3